SCA
REGN icon

Strategic Capital Alternatives’s Regeneron Pharmaceuticals REGN Stock Holding History

Strategic Capital Alternatives’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-125
Closed -$64K – 438
2015
Q2 		$64K Buy
+125
New +$61K 0.02% 276
2014
Q4 		– Sell
-125
Closed -$45K – 275
2014
Q3 		$45K Buy
+125
New +$41.9K 0.02% 242

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Strategic Capital Alternatives's REGN Position: Q3 2015 in Review

Strategic Capital Alternatives sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 125 shares — an estimated $64K sold.

Strategic Capital Alternatives first reported a position in REGN in Q3 2014 and held it in 2 quarters. The position peaked at $64K in Q2 2015. 563 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Strategic Capital Alternatives reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Strategic Capital Alternatives sold 125 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $64K.
  • Strategic Capital Alternatives first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Strategic Capital Alternatives's Regeneron Pharmaceuticals position peaked at $64K in Q2 2015.
  • 563 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Strategic Capital Alternatives's 13F filing for Q3 2015, filed 16 Nov 2015.